Senhance Surgical System

“This FDA clearance marks another milestone for Asensus Surgical and represents an additional indication expansion in the U.S. market,” said Anthony Fernando, Asensus Surgical President and CEO. “The Senhance System's precision and advanced digital capabilities make it uniquely suited for urological procedures, offering surgeons the benefit of digital tools and smaller instrumentation. We are excited to bring this technology to urologists and their patients across the United States.”

“Prior to our adoption of Senhance, we avoided adding a soft tissue robotics platform to our general surgery department because of a lack of meaningful benefits offered to our surgeons and patients by competing platforms. That has changed with Senhance and the platform’s innovative intelligent capabilities and laparoscopic foundation,” said Dr. David Gutierrez, Chief of General Surgery at Franklin Medical Center.